Sensus HealthcareSRTS +4.45%74 Receivables Turnover is 0.71 as of Mar. 2026. GuruFocus rates SRTS with a GF Score™ of 74/100 and a GF Value™ of $2.72 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Sensus Healthcare ranks worse than 90.9% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sensus Healthcare's Revenue for the
three
months ended in Mar. 2026 was $3.39 Mil. Sensus Healthcare's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4.81 Mil.
Hence, Sensus Healthcare's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.71.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sensus Healthcare Receivables Turnover Related Terms
Sensus Healthcare Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sensus Healthcare's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRTS vs COCH, QTI, MDAI: Receivables Turnover Comparison
For the Medical Devices subindustry, Sensus Healthcare's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensus Healthcare Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sensus Healthcare's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sensus Healthcare's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensus Healthcare (SRTS) has a Receivables Turnover of 0.71 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sensus Healthcare and its competitors. According to the industry distribution chart, Sensus Healthcare ranks #739 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 90.9%.
Is Sensus Healthcare's Receivables Turnover too high?
Sensus Healthcare's current Receivables Turnover is 0.71. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Sensus Healthcare's value of 0.71 is 87.1% below this industry median. Based on the distribution chart, Sensus Healthcare ranks #739 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sensus Healthcare has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's Receivables Turnover compare to COCH and QTI?
According to the Medical Devices & Instruments industry distribution chart, Sensus Healthcare ranks #739 out of 813 companies for Receivables Turnover. This places Sensus Healthcare in the lower half of its industry. The industry median Receivables Turnover is 5.51. Sensus Healthcare's value of 0.71 is 87.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sensus Healthcare's current Receivables Turnover of 0.71 is 87.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sensus Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sensus Healthcare's current Receivables Turnover is 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.72, compared to a current price of $3.05 — trading 12.1% above its estimated fair value. The current Receivables Turnover is 0.71 and 87.1% below the Medical Devices & Instruments industry median of 5.51. Sensus Healthcare's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current Receivables Turnover is 0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sensus Healthcare (SRTS) Overvalued in 2026?
Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued.
The current stock price of $3.05 is trading 12.1% above its estimated GF Value™ of $2.72.
GuruFocus considers Sensus Healthcare to be Modestly Overvalued.
Key valuation signals for SRTS:
Receivables Turnover: 0.71
GF Value™: $2.72 vs. price of $3.05 (12.1% above fair value)
Industry Position: 87.1% below the Medical Devices & Instruments median (#739 of 813)
No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
74GF Score
Get the complete analysis for SRTS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTS has been successfully added to your 
